Stempeutics Research Profile
Key Indicators
- Authorised Capital ₹ 65.00 Cr
- Paid Up Capital ₹ 59.67 Cr
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.18 Cr
- Revenue Growth 357.64%
- Profit Growth 49.71%
- Ebitda -41.07%
- Net Worth 52.97%
- Total Assets 5.03%
About Stempeutics Research
Stempeutics Research Private Limited (SRPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 16 January 2006 and has a history of 19 years and one month. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 65.00 Cr and a paid-up capital of Rs 59.67 Cr.
The company currently has active open charges totaling ₹2.18 Cr.
The Key Managerial Personnel (KMP) at Stempeutics Research Private Limited India is Kriti Agarwal as COMPANY SECRETARY. Anurag Bagaria, Manohar Narasimhan, Hebri Ballal, and Two other members serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U73100KA2006PTC038256
- Company No.
038256
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2006
- Date of AGM
19 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
What products or services does Stempeutics Research Private Limited offer?
Stempeutics Research Private Limited offers a wide range of products and services, including Natural Therapy Services, Stem Cell Therapy, Dermatology Treatment Services, Medical Surgery & Treatment Centres, Medical Facilities, Medical Equipment & Accessories, Life Support Machines, Hospital Equipment.
Who are the key members and board of directors at Stempeutics Research?
Executive Team (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Manohar Narasimhan ![]() | Managing Director | 26-Aug-2009 | Current |
Kriti Agarwal | Company Secretary | 21-Mar-2023 | Current |
Board Members (4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Umang Vohra ![]() | Director | 03-Jan-2024 | Current |
Anurag Bagaria ![]() | Director | 27-Jun-2019 | Current |
Hebri Ballal ![]() | Director | 19-Jan-2012 | Current |
Jaideep Gogtay ![]() | Nominee Director | 05-Jun-2011 | Current |
Financial Performance of Stempeutics Research.
Stempeutics Research Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 357.64% increase. The company also saw a substantial improvement in profitability, with a 49.71% increase in profit. The company's net worth Soared by an impressive increase of 52.97%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Stempeutics Research?
In 2023, Stempeutics Research had a promoter holding of 46.49% and a public holding of 53.51%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹2.18 Cr
₹0
Charges Breakdown by Lending Institutions
- Biotechnology Industry Research Assistance Council : 1.89 Cr
- Hdfc Bank Limited : 0.28 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
19 Nov 2021 | Hdfc Bank Limited | ₹2.84 M | Open |
31 Dec 2011 | Biotechnology Industry Research Assistance Council | ₹1.89 Cr | Open |
How Many Employees Work at Stempeutics Research?
Stempeutics Research has a workforce of 27 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Stempeutics Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stempeutics Research's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.